TrialThe Lancet. Neurology2021

Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial.

Günter U Höglinger et al.PubMed ↗Publisher ↗

No numbers read from the abstract.